Oncolys BioPharma Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥976M | ¥63M | ¥31M | ¥29M |
| Gross Profit | ¥338M | ¥31M | ¥31M | ¥29M |
| Operating Income | -¥1,205M | -¥1,930M | -¥1,681M | -¥2,024M |
| Pretax Income | -¥1,142M | -¥1,932M | -¥1,676M | -¥2,049M |
| Net Income | -¥1,149M | -¥1,939M | -¥1,685M | -¥2,058M |
| EPS | -¥66.31 | -¥108.92 | -¥77.17 | -¥80.00 |
| Operating Margin | -123.39% | -3,061.62% | -5,357.52% | -7,090.55% |
| Balance Sheet | ||||
| Total Assets | ¥2,651M | ¥2,041M | ¥3,199M | ¥4,556M |
| Total Equity | ¥2,159M | ¥1,474M | ¥2,752M | ¥4,000M |
| Total Liabilities | ¥492M | ¥567M | ¥447M | ¥556M |
| Cash | ¥1,711M | ¥1,533M | ¥2,411M | ¥3,675M |
| Interest-bearing Debt | ¥394M | ¥315M | ¥325M | ¥320M |
| Equity Ratio | 81.45% | 72.24% | 86.04% | 87.80% |
| D/E Ratio | 0.18 | 0.21 | 0.12 | 0.08 |
| Cash Flow | ||||
| Operating CF | -¥1,717M | -¥1,337M | -¥2,020M | -¥1,941M |
| Investing CF | ¥20M | -¥5M | -¥5M | -¥8M |
| Financing CF | -¥114M | ¥1,143M | ¥2,879M | ¥3,222M |
| Free CF | -¥1,718M | -¥1,343M | -¥2,024M | -¥1,944M |
| Efficiency | ||||
| ROE | -53.21% | -131.50% | -61.22% | -51.45% |
| ROA | -43.34% | -95.00% | -52.67% | -45.17% |
Latest IR Information
-
Announcement of sales commencement for Telomera-Syn® 注
Sales commencement of tumor-lytic virus Telomera-Syn® 注 in Japan. Sales partner FujiFilm Toyama Chemical, with initial delivery to medical institutions planned. A local therapeutic agent for esophageal cancer patients approved on June 8, expected to provide a new treatment option.
Read more -
Notice on the NHI Drug Price Listing and Insurance Coverage for Tumor Lysis Virus Telomerase Injection
Drug price listing and insurance coverage approved. Telomerase injection will be marketed through FujiFilm Toyama Chemical starting August 21, 2026. Revenue recognition is expected from the fiscal year ending December 2026.
Read more -
Financial Summary
Earnings briefing material for the June 2026 term. Indicates revenue and profit trends, segment contributions, financial position including cash and deposits, and 2026 outlook.
Read more -
Notice regarding the recognition of non-operating income and non-operating expenses
For the second quarter cumulative period of the 2026 fiscal year (2026/1/1-2026/6/30), non-operating income of 2000 ten thousand yen and non-operating expenses of 1300 ten thousand yen were recognized. The primary driver is gains from foreign exchange remeasurement of foreign-currency...
Read more -
Q2 FY2026 Financial Summary (Interim)
For FY2026 interim period (Q2), revenue was 503,090 thousand yen, operating loss 767,606 thousand yen, ordinary loss 760,604 thousand yen, and interim net loss 762,153 thousand yen. Compared with the same period prior year, revenue increased to 28,546 thousand yen,...
Read more
Latest News (5 items)
Company Information
About
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and aicardi-goutieres syndrome; OBP-702, which is in preclinical trial to treat pancreatic cancer; OBP-201, which is in preclinical trial to treat viral infections; OBP-702 for the treatment of ophthalmology which is in preclinical trial. In addition, it develops TelomeScan (OBP-401 and OBP-1101), which is in pilot study trial to treat cancer testing. The company was incorporated in 2004 and is headquartered in Minato, Japan.
